MieTon SRL
0.3 FTEMieTon reported total assets of 705,749 € at the end of the 2025 financial year (annual accounts filed with the NBB on 16 Jun 2026), with 0.3 full-time equivalent.
The score of MieTon shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +39 % Total assets +6 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
MieTon's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jun 2026
- Year ended 31 Dec 2024filed on 16 Jun 2025
- Year ended 31 Dec 2023filed on 05 Jul 2024
- Year ended 31 Dec 2022filed on 10 Aug 2023
- Year ended 31 Dec 2021filed on 27 Jul 2022
MieTon's financial analysis
- Solvency43.6%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of MieTon
MieTon's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0543.288.684
- VAT number
- BE0543288684
- Peppol
- Registered · 0208:0543288684 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Dec 2013
- Registered office
- 2323 Hoogstraten
- Size
- Micro · 0.3 FTE
- Latest accounts
- 2025 · filed on 16 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
MieTon (SRL) has been based in Hoogstraten since 2013, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 63,394 € and equity of 307,354 €; its revenue is not published. With 0.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 43.6%, below the median of its sector (44.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to MieTon
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie de Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Apotheek Sint-Katharina Retail sale of pharmaceutical products Kortrijk · balance sheet 701,231 €
- Piret Pharma Retail sale of pharmaceutical products Charleroi · balance sheet 675,213 €
- Mansion-Tassin Retail sale of pharmaceutical products Beyne-Heusay · balance sheet 648,936 €
- Pharmidable Retail sale of pharmaceutical products Namur · balance sheet 775,771 €
- Corum Retail sale of pharmaceutical products Ghent · balance sheet 641,387 €
- BDM Pharma Retail sale of pharmaceutical products Woluwe-Saint-Lambert · balance sheet 782,662 €
- Maudens Jeroen Retail sale of pharmaceutical products Sint-Genesius-Rode · balance sheet 633,969 €
Frequently asked questions about MieTon
What is the revenue of MieTon?
MieTon files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of MieTon?
In Belgium, the VAT number is the company number prefixed with BE: BE0543288684 for MieTon, if the company is VAT-registered. Its company number (CBE) is 0543.288.684.
Where is the registered office of MieTon?
According to the CBE register, the registered office of MieTon is in 2323 Hoogstraten.
What is the equity of MieTon?
At the close of the 2025 financial year, the equity of MieTon amounts to 307,354 €, a solvency of 43.6% of total assets.
How many people work at MieTon?
0.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages MieTon?
The register lists 2 active mandates at MieTon. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of MieTon
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →